Soluble Fas and Fas ligand in human tear fluid after photorefractive keratectomy

被引:7
|
作者
Tuominen, I
Vesaluoma, M
Teppo, AM
Grönhagen-Riska, C
Tervo, T
机构
[1] Univ Helsinki, Hosp Eye, Eye Bank, FIN-00029 Huch, Finland
[2] Helsinki Univ Hosp, Dept Med, Helsinki, Finland
关键词
D O I
10.1136/bjo.83.12.1360
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Background/aims-The Fas-Fas ligand system is thought to be involved in stromal cell apoptosis after corneal wounding. The aim was to measure changes in human tear fluid levels of soluble Fas (sFas) and Fas Ligand (sFasL) following myopic photorefractive keratectomy (PRK). Methods-Tear samples of 59 patients were collected preoperatively, and 1 or 2 days after PRK. Tear fluid sFas or sFasL concentrations were determined using sandwich ELISAs. Subsequently, tear flow corrected concentrations (releases) were calculated to compensate for the postoperative tear hypersecretion. Results-The preoperative tear fluid flows (TFF) were 6.4 (1.7) mu l/min (mean (SERI)) in sFas group (n = 18), and 7.5 (1.5) mu l/min in sFasL group (n = 39). Postoperatively TFFs increased to 37.9 (10.9) mu l/min (p = 0.003) and 58.3 (7.0) mu l/min (p = 0.000), respectively. The mean preoperative sFas concentration (24.3 (11.6) U/ml) decreased to 9.7 (4.1) U/ml (p = 0.001) postoperatively, and the mean sFasL concentration (299.1 (28.8) ng/l) to 118.7 (15.9) ng/l (p = 0.000). However, the release of both substances increased significantly: sFas from 87.3 (29.4) mU/min to 229.4 (82.9) mU/min (p = 0.002) and sFasL from 1620.6 (226.4) fg/min to 4777.1 (596.1) fg/min (p = 0.000). Conclusions-Both sFas and sFasL are normal constituents of human tears. Despite a decrease in concentrations related to reflex tears, the release of sFas and sFasL increases significantly after excimer laser photorefractive keratectomy, which suggests that they are involved in corneal healing after PRK in humans.
引用
收藏
页码:1360 / 1363
页数:4
相关论文
共 50 条
  • [41] Increased soluble Fas and Fas ligand levels in patients with nonalcoholic steatohepatitis
    Bhattacharyya, Tamali
    Yerian, Lisa
    Berk, Michael
    McCullough, Arthur
    Feldstein, Ariel
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 : S122 - S122
  • [42] Soluble Fas and Fas ligand in the joints of patients with rheumatoid arthritis and osteoarthritis
    Mrabet, D
    Hajri, R
    Hamzaoui, K
    Zakraoui, L
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 161 - 161
  • [43] Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia
    Fathi, Mina
    Amirghofran, Zahra
    Shahriari, Mehdi
    [J]. MEDICAL ONCOLOGY, 2012, 29 (03) : 2046 - 2052
  • [44] Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes
    Ottonello, L
    Tortolina, G
    Amelotti, M
    Dallegri, F
    [J]. JOURNAL OF IMMUNOLOGY, 1999, 162 (06): : 3601 - 3606
  • [45] Differential expressions of Fas and Fas ligand in human placenta
    Roh, CR
    Lee, JW
    Kang, BH
    Yang, SH
    Kim, BG
    Bae, DS
    Kim, JH
    Lee, JH
    [J]. JOURNAL OF KOREAN MEDICAL SCIENCE, 2002, 17 (02) : 213 - 216
  • [46] Fas and Fas ligand expression in human leukemias and lymphomas
    WeberNordt, RM
    Lang, S
    Mertelsmann, R
    Finke, J
    [J]. BLOOD, 1996, 88 (10) : 3171 - 3171
  • [47] CHANGES OF SOLUBLE FAS AND SOLUBLE FAS LIGANDIN SERUM AND PERITONEAL FLUID OF INFERTILEPATIENTS WITH ENDOMETRIOSIS
    令狐华
    徐小蓉
    骆建云
    庄琳
    [J]. Chinese Medical Sciences Journal, 2004, (01) : 56 - 59
  • [48] Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF
    Onalan, G
    Selam, B
    Baran, Y
    Cincik, M
    Onalan, R
    Gündüz, U
    Ural, AU
    Pabuccu, R
    [J]. HUMAN REPRODUCTION, 2005, 20 (09) : 2391 - 2395
  • [49] Soluble form of Fas and Fas ligand in serum and bronchoalveolar lavage fluid on individuals infected with human T-lymphotropic virus type 1
    Sakamoto, N
    Mukae, H
    Fujii, T
    Kakugawa, T
    Kaida, H
    Kadota, JI
    Kohno, S
    [J]. RESPIRATORY MEDICINE, 2004, 98 (03) : 213 - 219
  • [50] Serum levels of soluble Fas and soluble Fas ligand in patients with primary biliary cirrhosis.
    Deguchi, A
    Arima, K
    Nishioka, M
    [J]. HEPATOLOGY, 1999, 30 (04) : 566A - 566A